DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
GKT137831 is an investigational drug.
There have been 5 clinical trials for GKT137831. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2013.
The most common disease conditions in clinical trials are Liver Cirrhosis, Biliary, Cholangitis, and Diabetic Nephropathies. The leading clinical trial sponsors are Genkyotex SA, University of Alabama at Birmingham, and York Bioanalytical Solution.
There are six US patents protecting this investigational drug and fifty-seven international patents.
Recent Clinical Trials for GKT137831
|Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects||Genkyotex SA||Phase 1|
|GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis||University of Alabama at Birmingham||Phase 2|
|Bioequivalence Study||Eurofins Optimed||Phase 1|
Top disease conditions for GKT137831
Top clinical trial sponsors for GKT137831
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GKT137831||Start Trial||Pyrazolo pyridine derivatives as NADPH oxidase inhibitors||GENKYOTEX SA (Plan-les-Ouates, CH)||Start Trial|
|GKT137831||Start Trial||Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1||Eastern Virginia Medical School (Norfolk, VA)||Start Trial|
|GKT137831||Start Trial||Orvepitant for chronic cough therapy||NeRRe Therapeutics Limited (Herts, GB)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|